Abstract
Background: The effects of anti-dementia drugs on gait performance in Alzheimer disease (AD) are questionable. The objective of this meta-analysis was to examine the effects of anti-dementia drugs on the mean value and the coefficient of variation (CoV) of stride time among patients with AD while taking into account the type of drugs (i.e., acetylcholinesterase inhibitors [AChEIs] versus memantine) and the walking conditions (i.e., single versus dual-task). Methods: An English and French Medline search was conducted in March 2015, with no limit of date, using the Medical Subject Headings terms “pharmaceutical preparations” combined with terms "Pharmaceutical preparations" OR "Therapeutic uses" OR "Drug substitution" OR "Drugs essential" OR "Drugs, Generic" OR "Psychotropic drugs" combined with "Delirium” OR “Dementia” OR “Amnestic” OR “Cognitive disorders" AND "Gait" OR "Gait Ataxia" OR "Gait disorders, Neurologic" OR “Gait apraxia”. Fixed-effects meta-analyses were used to examine anti-dementia drugs-related changes in mean value and CoV of stride time. Results: Of the 66 identified abstracts, 5 (7.6%) were included in the meta-analysis. Inter-group comparison of between-visit change underscored a significant decrease in CoV of stride time (P<0.004) in intervention group compared to control group, whatever the pooled analysis considered, but no significant change in the mean value (P>0.06). Intra-group changes in stride time parameters following the use of anti-dementia drugs showed a significant decrease for memantine (P<0.001) and while pooling AChEIs and memantine (P<0.001) under single task condition. Under dual task condition, only AChEIs improved significantly stride time parameters (P=0.002). Conclusion: Anti-dementia drugs demonstrated a significant improvement of gait performance with specific class effect depending on the walking conditions and on the type of stride time parameters considered.
Keywords: Alzheimer disease, anti-dementia drugs, dual task, gait disorders, meta-analysis, older adults.
Current Alzheimer Research
Title:Anti-dementia drugs-related changes in gait performance while single and dual tasking in patients with Alzheimer disease: a meta-analysis
Volume: 12 Issue: 8
Author(s): O. Beauchet, C. P. Launay, M Montero-Odasso, C Annweiler and G. Allali
Affiliation:
Keywords: Alzheimer disease, anti-dementia drugs, dual task, gait disorders, meta-analysis, older adults.
Abstract: Background: The effects of anti-dementia drugs on gait performance in Alzheimer disease (AD) are questionable. The objective of this meta-analysis was to examine the effects of anti-dementia drugs on the mean value and the coefficient of variation (CoV) of stride time among patients with AD while taking into account the type of drugs (i.e., acetylcholinesterase inhibitors [AChEIs] versus memantine) and the walking conditions (i.e., single versus dual-task). Methods: An English and French Medline search was conducted in March 2015, with no limit of date, using the Medical Subject Headings terms “pharmaceutical preparations” combined with terms "Pharmaceutical preparations" OR "Therapeutic uses" OR "Drug substitution" OR "Drugs essential" OR "Drugs, Generic" OR "Psychotropic drugs" combined with "Delirium” OR “Dementia” OR “Amnestic” OR “Cognitive disorders" AND "Gait" OR "Gait Ataxia" OR "Gait disorders, Neurologic" OR “Gait apraxia”. Fixed-effects meta-analyses were used to examine anti-dementia drugs-related changes in mean value and CoV of stride time. Results: Of the 66 identified abstracts, 5 (7.6%) were included in the meta-analysis. Inter-group comparison of between-visit change underscored a significant decrease in CoV of stride time (P<0.004) in intervention group compared to control group, whatever the pooled analysis considered, but no significant change in the mean value (P>0.06). Intra-group changes in stride time parameters following the use of anti-dementia drugs showed a significant decrease for memantine (P<0.001) and while pooling AChEIs and memantine (P<0.001) under single task condition. Under dual task condition, only AChEIs improved significantly stride time parameters (P=0.002). Conclusion: Anti-dementia drugs demonstrated a significant improvement of gait performance with specific class effect depending on the walking conditions and on the type of stride time parameters considered.
Export Options
About this article
Cite this article as:
Beauchet O., Launay P. C., Montero-Odasso M, Annweiler C and Allali G., Anti-dementia drugs-related changes in gait performance while single and dual tasking in patients with Alzheimer disease: a meta-analysis, Current Alzheimer Research 2015; 12 (8) . https://dx.doi.org/10.2174/1567205012666150710111341
DOI https://dx.doi.org/10.2174/1567205012666150710111341 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neurodegeneration with Dementia: From Fundamentals of Pathology to Clinical Imaging by MRI and SPECT.
Current Medical Imaging Colloidal Supramolecular Aggregates for Therapeutic Application in Neuromedicine
Current Medicinal Chemistry Microglial dependent protective effects of neuroactive steroids
CNS & Neurological Disorders - Drug Targets Interactions Between Plasma Proteins and Naturally Occurring Polyphenols
Current Drug Metabolism Bioactivity Guided Isolation of Quercetin as Anxiolytic Compound from Elaeocarpus ganitrus Beads
The Natural Products Journal Role of Trisomy 21 Mosaicism in Sporadic and Familial Alzheimer’s Disease
Current Alzheimer Research Release of Adenosine and ATP During Ischemia and Epilepsy
Current Neuropharmacology Inhibition of Tau Protein Aggregation by Rhodanine-based Compounds Solubilized Via Specific Formulation Additives to Improve Bioavailability and Cell Viability
Current Alzheimer Research Tau Pathology and Future Therapeutics
Current Alzheimer Research Heparin Oligosaccharides as Potential Therapeutic Agents in Senile Dementia
Current Pharmaceutical Design Significant Overlapping Modules and Biological Processes Between Stroke and Coronary Heart Disease
CNS & Neurological Disorders - Drug Targets Clinical and Environmental Correlates of Serum BDNF: A Descriptive Study with Plausible Implications for AD Research
Current Alzheimer Research Erythropoietin and Oxidative Stress
Current Neurovascular Research 5-Hydroxymethylfurfural (HMF) in Organic Synthesis: A Review of its Recent Applications Towards Fine Chemicals
Current Organic Synthesis Recent Advances in Progressive Supranuclear Palsy: A Review
Current Alzheimer Research Hyper-Coagulable Profile with Elevated Pro-Thrombotic Biomarkers and Increased Cerebro- and Cardio-Vascular Disease Risk Exist Among Healthy Dyslipidemic Women
Current Neurovascular Research Disruption of Circadian Rhythms and Delirium, Sleep Impairment and Sepsis in Critically ill Patients. Potential Therapeutic Implications for Increased Light-Dark Contrast and Melatonin Therapy in an ICU Environment
Current Pharmaceutical Design An Insight in Pathophysiological Mechanism of Alzheimer’s Disease and its Management Using Plant Natural Products
Mini-Reviews in Medicinal Chemistry Mitochondria as a Therapeutic Target for Aging and Neurodegenerative Diseases
Current Alzheimer Research Effect of PSEN1 mutations on MAPT methylation in early-onset Alzheimer’s disease
Current Alzheimer Research